

Amit M Oza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6946256/publications.pdf>

Version: 2024-02-01

197
papers

24,979
citations

20759

60
h-index

7333

152
g-index

198
all docs

198
docs citations

198
times ranked

20052
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164.	13.9	1,860
2	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	13.9	1,854
3	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496.	13.9	1,843
4	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	5.1	1,376
5	Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. <i>Lancet</i> , The, 2014, 383, 1721-1730.	6.3	1,361
6	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	6.3	1,261
7	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
8	Epithelial ovarian cancer. <i>Lancet</i> , The, 2019, 393, 1240-1253.	6.3	1,039
9	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology</i> , The, 2011, 12, 852-861.	5.1	1,028
10	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	5.1	975
11	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 280-304.	157.7	821
12	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 928-936.	5.1	661
13	Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 2059-2069.	0.8	613
14	Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. <i>Journal of Clinical Oncology</i> , 2008, 26, 76-82.	0.8	511
15	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 87-97.	5.1	491
16	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 636-648.	5.1	366
17	Phase II Study of Temozolomide in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3278-3285.	0.8	321
18	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	7.7	310

#	ARTICLE	IF	CITATIONS
19	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 799-808.	5.1	279
20	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	7.7	278
21	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic <i>BRCA1</i> or <i>BRCA2</i> mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	0.6	222
22	A Phase III Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4095-4106.	3.2	213
23	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	3.6	211
24	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4371-4380.	0.8	203
25	Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1266-1274.	0.8	175
26	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. <i>Lancet Oncology</i> , The, 2015, 16, e32-e42.	5.1	152
27	Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. <i>Journal of Clinical Oncology</i> , 2008, 26, 4319-4325.	0.8	137
28	Treatment strategies for endometrial cancer: current practice and perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 47-58.	0.9	133
29	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	3.2	126
30	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 236-243.	5.1	125
31	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 397, 281-292.	6.3	125
32	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <i>BRCA</i> -Mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1574-1582.	3.2	124
33	Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. <i>Cancer</i> , 2007, 109, 692-702.	2.0	122
34	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173776.	3.4	116
35	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
36	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , 2014, 120, 3932-3939.	2.0	114

#	ARTICLE	IF	CITATIONS
37	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017, 23, 4086-4094.	3.2	114
38	Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1607.	1.7	104
39	Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3582.	0.8	97
40	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2018, 19, 1117-1125.	5.1	95
41	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. <i>Gynecologic Oncology</i> , 2010, 117, 37-40.	0.6	92
42	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S14-S19.	1.2	87
43	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 145, 584-594.	0.6	85
44	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 135, 184-189.	0.6	84
45	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. <i>Clinical Cancer Research</i> , 2020, 26, 4206-4215.	3.2	84
46	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	0.6	81
47	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. <i>Gynecologic Oncology</i> , 2013, 130, 25-30.	0.6	79
48	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Oncolimmunology</i> , 2015, 4, e1026529.	2.1	79
49	Somatic <i>BRCA1/2</i> Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. <i>Journal of Clinical Oncology</i> , 2017, 35, 1240-1249.	0.8	79
50	Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). <i>European Journal of Cancer</i> , 2010, 46, 1365-1373.	1.3	75
51	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	0.8	75
52	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology</i> , The, 2015, 16, e43-e52.	5.1	72
53	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. <i>Genome Medicine</i> , 2018, 10, 81.	3.6	72
54	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 62-69.	0.6	70

#	ARTICLE	IF	CITATIONS
55	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	1.3	70
56	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	5.1	70
57	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 465-478.	5.1	70
58	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	5.1	68
59	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4767-4776.	3.2	68
60	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. <i>Gynecologic Oncology</i> , 2015, 137, 216-222.	0.6	65
61	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. <i>Cancer</i> , 2014, 120, 603-610.	2.0	64
62	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3528-3537.	0.8	64
63	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4549-4558.	3.2	63
64	A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia. <i>Gynecologic Oncology</i> , 2015, 138, 55-61.	0.6	62
65	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 50-58.	1.2	61
66	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5508-5508.	0.8	60
67	Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials. <i>Cancer</i> , 2015, 121, 1737-1746.	2.0	59
68	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. <i>Gynecologic Oncology</i> , 2014, 134, 274-280.	0.6	58
69	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. <i>Investigational New Drugs</i> , 2016, 34, 355-363.	1.2	58
70	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 1669-1678.	1.1	55
71	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 903-915.	1.2	52
72	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	1.2	50

#	ARTICLE	IF	CITATIONS
73	Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study. <i>Cancer</i> , 2014, 120, 335-343.	2.0	49
74	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. <i>Cancers</i> , 2019, 11, 416.	1.7	49
75	Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. <i>Gynecologic Oncology</i> , 2015, 138, 285-291.	0.6	47
76	The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 238-244.	1.2	47
77	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , 2018, 24, 6168-6174.	3.2	44
78	Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. <i>European Journal of Cancer</i> , 2016, 59, 99-108.	1.3	40
79	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 53-60.	0.6	40
80	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 632-642.	5.1	40
81	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1589-1594.	1.2	40
82	ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 121-131.	1.3	38
83	Better Therapeutic Trials in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju029-dju029.	3.0	36
84	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
85	Niraparib for the treatment of ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 631-640.	0.9	35
86	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , 2013, 130, 289-294.	0.6	34
87	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	1.1	32
88	Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 36-44.	3.2	32
89	Ovarian cancer treatment: The end of empiricism?. <i>Cancer</i> , 2015, 121, 3203-3211.	2.0	30
90	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 346-352.	1.2	29

#	ARTICLE	IF	CITATIONS
91	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. <i>Oncologist</i> , 2018, 23, 203-213.	1.9	28
92	High <i>EMSY</i> expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , 2019, 125, 2772-2781.	2.0	28
93	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3494-3505.	0.8	28
94	Advances in ovarian cancer, from biology to treatment. <i>Nature Cancer</i> , 2021, 2, 6-8.	5.7	26
95	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 111-117.	0.4	25
96	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. <i>Obstetrics and Gynecology International</i> , 2018, 2018, 1-10.	0.5	23
97	COVID-19 Testing in Patients with Cancer: Does One Size Fit All?. <i>Clinical Cancer Research</i> , 2020, 26, 4737-4742.	3.2	23
98	Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 275-282.	0.6	22
99	Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. <i>Gynecologic Oncology</i> , 2014, 133, 460-466.	0.6	21
100	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIQ Symptom Benefit Study. <i>Oncologist</i> , 2017, 22, 1117-1124.	1.9	20
101	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	0.6	20
102	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i> -mutated, high-grade ovarian cancer, and an update on safety. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1396-1404.	1.2	19
103	QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5514-5514.	0.8	19
104	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. <i>Journal of Translational Medicine</i> , 2016, 14, 83.	1.8	18
105	Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 927-943.	1.4	18
106	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. <i>Blood</i> , 2016, 128, 4526-4526.	0.6	17
107	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018, 11, 65.	0.7	16
108	Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e1066-e1075.	2.5	16

#	ARTICLE	IF	CITATIONS
109	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020, 26, 2477-2486.	3.2	16
110	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. <i>Frontiers in Oncology</i> , 2016, 6, 119.	1.3	15
111	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. <i>Cancer</i> , 2020, 126, 4886-4894.	2.0	15
112	Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, B109-B109.	1.9	15
113	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5518-5518.	0.8	15
114	Safety evaluation of olaparib for treating ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1305-1316.	1.0	14
115	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	0.6	14
116	Recent advances in systemic therapy for advanced endometrial cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 494-500.	1.1	13
117	Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?. <i>Cancers</i> , 2020, 12, 3296.	1.7	13
118	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e152-e166.	1.8	12
119	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. <i>Oncologist</i> , 2021, 26, e2254-e2264.	1.9	12
120	Aspirin in Prevention of Ovarian Cancer: Are We at the Tipping Point?. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt453-djt453.	3.0	11
121	Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions. <i>Gynecologic Oncology</i> , 2016, 140, 90-94.	0.6	11
122	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 71-83.	0.5	11
123	Targeting Angiogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1041-1055.	0.9	11
124	Olaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 497-508.	0.5	10
125	The role of niraparib for the treatment of ovarian cancer. <i>Future Oncology</i> , 2018, 14, 2565-2577.	1.1	10
126	Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5025-5025.	0.8	10

#	ARTICLE	IF	CITATIONS
127	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 136, 311-316.	0.6	9
128	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e247-e257.	1.8	9
129	New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?. <i>Current Oncology Reports</i> , 2016, 18, 23.	1.8	9
130	Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. <i>Gynecologic Oncology</i> , 2020, 157, 745-753.	0.6	9
131	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , 2021, 161, 221-227.	0.6	9
132	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	1.3	9
133	Clinical data from the DeCidE ¹ trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5510-5510.	0.8	9
134	Current and emerging treatment options in the management of advanced ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1063-1076.	0.9	8
135	Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004341.	0.5	8
136	Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?. <i>Clinical Cancer Research</i> , 2020, 26, 523-525.	3.2	8
137	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e247-e257.	1.8	8
138	A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. <i>Investigational New Drugs</i> , 2016, 34, 231-235.	1.2	7
139	Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. <i>Gynecologic Oncology</i> , 2019, 153, 304-311.	0.6	7
140	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	1.2	7
141	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	0.6	7
142	Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5547-5547.	0.8	7
143	Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. <i>Gynecologic Oncology</i> , 2015, 138, 235-237.	0.6	6
144	Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study. <i>Radiotherapy and Oncology</i> , 2017, 124, 74-79.	0.3	6

#	ARTICLE	IF	CITATIONS
145	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019, 8, 200.	1.8	6
146	DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1824-1828.	1.2	6
147	Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 139-143.	1.2	6
148	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5610-TPS5610.	0.8	6
149	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. <i>Cancer</i> , 2021, 127, 3082-3091.	2.0	6
150	Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 1513-1517.	0.8	6
151	Ethical frameworks in clinical research processes during COVID-19: a scoping review. <i>BMJ Open</i> , 2021, 11, e047076.	0.8	6
152	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6068-6068.	0.8	6
153	Advances in prediction for ovarian cancer treatment stratification. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 75-76.	12.5	5
154	Optimizing clinical research procedures in public health emergencies. <i>Medicinal Research Reviews</i> , 2021, 41, 725-738.	5.0	5
155	Moving From Mutation to Actionability. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 495-503.	1.8	4
156	Targeting TGF β Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?. <i>Clinical Cancer Research</i> , 2019, 25, 5432-5434.	3.2	4
157	Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study. <i>Journal of Surgical Oncology</i> , 2019, 120, 786-793.	0.8	4
158	Conservative management of adnexal masses. <i>Lancet Oncology</i> , The, 2019, 20, 326-327.	5.1	4
159	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 539-545.	0.6	4
160	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. <i>Modern Pathology</i> , 2020, 33, 2361-2377.	2.9	4
161	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	1.3	4
162	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. <i>Cancer Research Communications</i> , 2022, 2, 293-306.	0.7	4

#	ARTICLE	IF	CITATIONS
163	Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. <i>Cancer</i> , 2015, 121, 413-422.	2.0	3
164	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 994-1002.	0.4	3
165	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2021, 28, 661-670.	0.9	3
166	Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 658.e1-658.e9.	0.7	3
167	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. <i>Gynecologic Oncology</i> , 2021, 162, 97-106.	0.6	3
168	Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5518-5518.	0.8	3
169	Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5541-5541.	0.8	3
170	Targeting the microenvironment in ovarian cancer. <i>Lancet Oncology</i> , The, 2015, 16, 485-486.	5.1	2
171	Emerging growth factor receptor antagonists for ovarian cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 1-16.	1.0	2
172	Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4432-4434.	3.2	2
173	Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3072-3072.	0.8	2
174	Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5535-5535.	0.8	2
175	Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 164-164.	0.8	2
176	Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5581-5581.	0.8	2
177	Non-target progression – The fine line between objectivity and subjectivity. <i>European Journal of Cancer</i> , 2014, 50, 3271-3272.	1.3	1
178	Discrepancies in drug approvals: A global dilemma. <i>Cancer</i> , 2015, 121, 3360-3361.	2.0	1
179	Resisting RECIST – Uniformity Versus Clinical Validity. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1619-1627.	1.2	1
180	Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1256-1257.	1.2	1

#	ARTICLE	IF	CITATIONS
181	Moving Beyond BRCAâ€”Incorporating Molecular Assays into Ovarian Cancer Trials. <i>Clinical Cancer Research</i> , 2020, 26, 5271-5273.	3.2	1
182	Impact of an internal medicine nocturnist service on care of patients with cancer at a large Canadian teaching hospital: a quality-improvement study. <i>CMAJ Open</i> , 2021, 9, E667-E672.	1.1	1
183	Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100729.	0.3	1
184	Targeted Therapy in Management of Endometrial Cancer. , 2020, , 249-276.		1
185	With Our Powers Combined. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 511-520.	1.0	1
186	Updates on systemic therapy for cervical cancer.. <i>Indian Journal of Medical Research</i> , 2021, 154, 293-302.	0.4	1
187	Double trouble: whole genome doubling distinguishes early from late ovarian cancer. <i>Clinical Cancer Research</i> , 2022, , .	3.2	1
188	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. <i>Current Oncology</i> , 2022, 29, 4354-4369.	0.9	1
189	PEGylated liposomal doxorubicin: present and future role in the treatment of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 21-31.	0.4	0
190	The role of cediranib in ovarian cancer: current status and further investigation. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 855-865.	0.5	0
191	DNA Repair Defects for Therapy in Ovarian Cancer: The BRCA1/2 and PARP Inhibitor Story. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 65-75.	0.1	0
192	Rucaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 151-161.	0.5	0
193	Adjuvant treatment in early stage cervical cancerâ€”does more equal better?. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1467-1468.	1.2	0
194	Quality assurance metrics in clinical trial conduct.. <i>Journal of Clinical Oncology</i> , 2016, 34, 274-274.	0.8	0
195	Prognostic effects of clinical and tumor (t) factors in bevacizumab (BEV)-treated patients (pts) with ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5556-5556.	0.8	0
196	Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003082.	1.2	0
197	Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5544-5544.	0.8	0